Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milademetan versus trabectedin in dedifferentiated liposarcoma
2021-001394-23Phase 3Terminated
- Sponsor
- Rain Oncology Inc.
- Start
- Jul 2021
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in dedifferentiated liposarcoma (DDL) comparing Milademetan with Trabectedin control (2 arms). Primary endpoint: Progression-free survival. Started Jul 2021; status: terminated.
02
Drugs
milademetantrabectedin
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on 2021-001394-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001394-23.